Additional file 1 of Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada

Additional file 1: Tables S1-S5 and Figures S1-S4. Table S1. Model inputs. Table S2. Optimal nirsevimab coverage with decreasing price per dose. Table S3. Optimal RSVpreF coverage with decreasing price per dose. Table S4. Optimal strategy with varying hospitalisation rates. Table S5. Optimal strategy with varying product uptake. Figure S1. Efficacy sigmoid decay functions. Figure S2. Cost-effectiveness results with waning vaccine efficacy. Figure S3. Cost-effectiveness results from societal perspective. Figure S4. Cost-effectiveness results from expanded societal perspective.